Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR750 Bridging Study in Healthy Subjects
NCT05753033Phase 1Completed
- Sponsor
- Shanghai SIMRD Biotechnology Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuropathic pain comparing SR750 with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 4 more. Started Feb 2023; status: completed.
02
Drugs
SR750
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05753033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753033.